Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€26.75

€26.75

0.940%
0.25
0.940%
€45.00
 
08.12.23 / Tradegate WKN: 852009 / Symbol: PFE / Name: Pfizer / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Pfizer Inc. Stock

The Pfizer Inc. stock is trending slightly upwards today, with an increase of €0.25 (0.940%) compared to yesterday's price.
With 21 Buy predictions and 2 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 45 € there is a hugely positive potential of 68.22% for Pfizer Inc. compared to the current price of 26.75 €.
Our community identified positive and negative aspects for Pfizer Inc. stock for the coming years. 14 users see the criterium "Worthwhile Investment for the next years" as a plus for the Pfizer Inc. stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.

Pros and Cons of Pfizer Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Pfizer Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Pfizer Inc. 0.940% 0.564% -7.118% -45.497% -44.131% -23.908% -26.881%
Biogen Inc. 0.720% 3.061% 2.680% -18.846% -13.254% 9.189% -22.576%
Elanco Animal Health Inc. 0.840% 4.912% 17.949% 0.623% 5.803% -51.392% -
AbbVie Inc. 1.600% 5.159% 4.525% -11.854% -8.912% 55.906% 79.883%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon first glance, the financials of Pfizer Inc. (NYSE: PFE) appear to be strong, showcasing a robust position in the pharmaceuticals industry. As a prominent player, Pfizer has consistently demonstrated growth in its total assets and revenue, laying the foundation for a favorable outlook on the company's performance. As we dive deeper into the financial statements, it becomes essential to analyze the pros and cons to acquire a comprehensive understanding of Pfizer's financial health and future potential.

*Pros: *

Growing Total Assets and Shareholders' Equity: The company's total assets have grown consistently over the past three years, from approximately €154.2 billion in 2020 to €181.5 billion in 2021, and reaching a notable USD 197.2 billion in 2022. Such growth indicates strong financial management and an increased capacity to generate income. Similarly, the total stockholder equity has also risen, reflecting the company's ability to create value for its shareholders.

Comments

Prediction Buy
Perf. (%) -2.19%
Target price 38.833
Change
Ends at 04.12.24

Pfizer Inc. (NYSE: PFE) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $42.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -2.19%
Target price 68.490
Change
Ends at 20.11.24

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $75.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -11.10%
Target price 39.736
Change
Ends at 17.10.24

Pfizer Inc. (NYSE: PFE) had its price target lowered by analysts at Truist Financial Co. from $62.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for PFE provided by MarketBeat
Show more

News

Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?: https://g.foolcdn.com/editorial/images/757218/chemist-team-looking-beaker-of-green-chemical.jpg
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?

On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myelomahttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma


Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab). ELREFXIO is a targeted immunotherapy for the

Simply Good Foods: Winner in the Ozempic Weight-Loss Trend: https://www.marketbeat.com/logos/articles/med_20231203163352_chart-smpl2.jpg
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend

Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication trend led by Ozempic, Novo Nordisk A/S (NYSE: NVO)